• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anakinra in COVID-19: A step closer to the cure.

作者信息

Barkas Fotios, Christaki Eirini, Liberopoulos Evangelos, Kosmidou Maria, Milionis Haralampos

机构信息

Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

出版信息

Eur J Intern Med. 2022 Feb;96:113-114. doi: 10.1016/j.ejim.2021.11.005. Epub 2021 Nov 11.

DOI:10.1016/j.ejim.2021.11.005
PMID:34794858
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8580858/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2168/8580858/f4639f569f61/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2168/8580858/f4639f569f61/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2168/8580858/f4639f569f61/gr1_lrg.jpg

相似文献

1
Anakinra in COVID-19: A step closer to the cure.阿那白滞素用于治疗新冠肺炎：向治愈更近一步。
Eur J Intern Med. 2022 Feb;96:113-114. doi: 10.1016/j.ejim.2021.11.005. Epub 2021 Nov 11.
2
Anakinra in COVID-19-How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarro-Millán et al.阿那白滞素在新型冠状病毒肺炎中的应用——如何解读血清肝酶升高：对纳瓦罗 - 米兰等人文章的评论
Arthritis Rheumatol. 2021 Mar;73(3):549. doi: 10.1002/art.41525. Epub 2021 Jan 29.
3
Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study.阿那白滞素治疗需要氧疗的重症 COVID-19 肺炎住院患者：一项前瞻性、开放标签、干预性研究的结果。
Int J Infect Dis. 2021 Feb;103:288-296. doi: 10.1016/j.ijid.2020.11.149. Epub 2020 Nov 17.
4
IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.白细胞介素-1 受体拮抗剂阿那白滞素治疗 COVID-19 急性呼吸窘迫综合征：一项回顾性观察研究。
J Immunol. 2021 Apr 1;206(7):1569-1575. doi: 10.4049/jimmunol.2001126. Epub 2021 Feb 5.
5
Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.生物标志物指导下低剂量阿那白滞素在一名患有重症 COVID-19 和细胞因子释放综合征的急性呼吸窘迫综合征患者中的应用。
Scand J Rheumatol. 2020 Sep;49(5):414-416. doi: 10.1080/03009742.2020.1789734. Epub 2020 Sep 11.
6
Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.皮下注射阿那白滞素单一疗法成功治疗重症新型冠状病毒肺炎。
Rheumatology (Oxford). 2020 Aug 1;59(8):2171-2173. doi: 10.1093/rheumatology/keaa318.
7
Anakinra: a silver lining in COVID-19?阿那白滞素：新冠疫情中的一线希望？
Crit Care. 2020 Oct 6;24(1):598. doi: 10.1186/s13054-020-03312-8.
8
Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe Covid-19?安那白滞素和皮质类固醇治疗对重症 COVID-19 孕妇是否有效？
Women Health. 2021 Oct;61(9):872-879. doi: 10.1080/03630242.2021.1981517. Epub 2021 Sep 22.
9
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment.阿那白滞素作为托珠单抗难治的新型冠状病毒肺炎相关严重急性呼吸道感染治疗的潜在替代方案：评论
Reumatol Clin (Engl Ed). 2023 Feb;19(2):120-121. doi: 10.1016/j.reumae.2022.06.001. Epub 2022 Jun 22.
10
Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection.阿那白滞素在治疗新型冠状病毒严重呼吸道感染中的应用。
Reumatol Clin (Engl Ed). 2023 Feb;19(2):121. doi: 10.1016/j.reumae.2022.02.001. Epub 2022 Jun 24.

引用本文的文献

1
COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters.COVID-19 生物标志物在患者分层和靶向治疗之间的十字路口：经过验证和提出的参数的作用。
Int J Mol Sci. 2023 Apr 12;24(8):7099. doi: 10.3390/ijms24087099.
2
Drugs for COVID-19: An Update.抗新冠病毒药物进展
Molecules. 2022 Dec 5;27(23):8562. doi: 10.3390/molecules27238562.
3
Discovery of Nitro-azolo[1,5-]pyrimidines with Anti-Inflammatory and Protective Activity against LPS-Induced Acute Lung Injury.

本文引用的文献

1
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.早期使用依那西普联合可溶性尿激酶型纤溶酶原激活物受体血浆水平指导 COVID-19 治疗：一项双盲、随机对照 3 期试验。
Nat Med. 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Epub 2021 Sep 3.
2
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis.阿那白滞素对新型冠状病毒肺炎患者死亡率的影响：一项系统评价和患者水平的荟萃分析。
Lancet Rheumatol. 2021 Oct;3(10):e690-e697. doi: 10.1016/S2665-9913(21)00216-2. Epub 2021 Aug 9.
3
具有抗炎及对脂多糖诱导的急性肺损伤保护活性的硝基-氮杂环并[1,5-]嘧啶的发现
Pharmaceuticals (Basel). 2022 Apr 27;15(5):537. doi: 10.3390/ph15050537.
Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma.
阿那白滞素或托珠单抗用于预防新冠死亡？一个重大难题。
Eur J Intern Med. 2021 Aug;90:107-108. doi: 10.1016/j.ejim.2021.05.039. Epub 2021 Jun 5.
4
Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis.阿那白滞素用于住院的非插管2019冠状病毒病患者：一项系统评价和荟萃分析。
Rheumatology (Oxford). 2021 Dec 1;60(12):5527-5537. doi: 10.1093/rheumatology/keab447.
5
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
6
Tocilizumab in COVID-19: some clarity amid controversy.托珠单抗治疗新冠病毒病：争议中渐趋明晰
Lancet. 2021 May 1;397(10285):1599-1601. doi: 10.1016/S0140-6736(21)00712-1.
7
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.阿那白滞素治疗 COVID-19 患者：非随机队列研究的荟萃分析。
Eur J Intern Med. 2021 Apr;86:34-40. doi: 10.1016/j.ejim.2021.01.016. Epub 2021 Feb 5.
8
A living WHO guideline on drugs for covid-19.关于新冠病毒药物的世界卫生组织实用指南。
BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379.
9
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study.新型冠状病毒肺炎相关的炎症风暴与患者治疗升级：一项回顾性纵向队列研究
Lancet Rheumatol. 2020 Oct;2(10):e594-e602. doi: 10.1016/S2665-9913(20)30275-7. Epub 2020 Aug 21.
10
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.可溶性尿激酶型纤溶酶原激活物受体（suPAR）作为新型冠状病毒肺炎患者严重呼吸衰竭的早期预测指标
Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4.